MTN-020 - ASPIRE
ASPIRE - A Study to Prevent Infection with a Ring for Extended Use – is a Phase III safety and effectiveness trial of a vaginal ring containing the antiretroviral dapivirine that opened in August 2012 and enrolled 2,629 women at several sites in Africa. The dapivirine vaginal ring was developed by the International Partnership for Microbicides, which is conducting another Phase III trial, The Ring Study, in parallel with ASPIRE.
Researchers complete ASPIRE Phase III trial of the dapivirine vaginal ring for HIV prevention in women; results are expected early 2016
Phase III Trial of Dapivirine Ring Begins in Africa: ASPIRE testing new HIV prevention approach for women